• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    1/8/24 4:31:09 PM ET
    $ATNF
    $BWAY
    $ELEV
    $LIFW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ATNF alert in real time by email

    Gainers

    • Syra Health (NASDAQ:SYRA) shares rose 21.2% to $1.5 during Monday's after-market session. The market value of their outstanding shares is at $9.6 million.
    • Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 13.15% to $2.58. The market value of their outstanding shares is at $9.3 million.
    • MaxCyte (NASDAQ:MXCT) shares rose 10.23% to $5.06. The company's market cap stands at $524.0 million.
    • Elevation Oncology (NASDAQ:ELEV) shares rose 7.73% to $1.95. The market value of their outstanding shares is at $82.7 million.
    • MSP Recovery (NASDAQ:LIFW) stock increased by 5.82% to $2.0. The market value of their outstanding shares is at $28.8 million.
    • BrainsWay (NASDAQ:BWAY) stock moved upwards by 5.62% to $7.51. The company's market cap stands at $124.8 million.

    Losers

    • Synaptogenix (NASDAQ:SNPX) shares declined by 8.5% to $0.23 during Monday's after-market session. The market value of their outstanding shares is at $4.6 million.
    • OKYO Pharma (NASDAQ:OKYO) stock decreased by 7.81% to $1.74. The company's market cap stands at $57.9 million.
    • LumiraDx (NASDAQ:LMDX) shares decreased by 7.5% to $0.01. The market value of their outstanding shares is at $4.7 million.
    • Soligenix (NASDAQ:SNGX) stock decreased by 5.2% to $0.89. The company's market cap stands at $9.2 million.
    • 180 Life Sciences (NASDAQ:ATNF) stock fell 5.14% to $0.19. The market value of their outstanding shares is at $1.8 million.
    • Vigil Neuroscience (NASDAQ:VIGL) stock declined by 4.96% to $3.45. The company's market cap stands at $123.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATNF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNF
    $BWAY
    $ELEV
    $LIFW

    CompanyDatePrice TargetRatingAnalyst
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    OKYO Pharma Limited
    $OKYO
    12/8/2025$5.00Buy
    B. Riley Securities
    MaxCyte Inc.
    $MXCT
    8/11/2025Buy → Neutral
    BTIG Research
    MaxCyte Inc.
    $MXCT
    8/7/2025Outperform → Mkt Perform
    William Blair
    MaxCyte Inc.
    $MXCT
    7/22/2025$6.00Overweight
    Stephens
    Vigil Neuroscience Inc.
    $VIGL
    5/28/2025$8.00Buy → Hold
    Stifel
    Elevation Oncology Inc.
    $ELEV
    3/24/2025$5.00 → $1.00Overweight → Equal-Weight
    Stephens
    Elevation Oncology Inc.
    $ELEV
    3/21/2025$1.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $ATNF
    $BWAY
    $ELEV
    $LIFW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on OKYO Pharma with a new price target

    Piper Sandler initiated coverage of OKYO Pharma with a rating of Overweight and set a new price target of $7.00

    2/20/26 8:25:04 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on OKYO Pharma with a new price target

    B. Riley Securities initiated coverage of OKYO Pharma with a rating of Buy and set a new price target of $5.00

    12/8/25 8:35:27 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MaxCyte downgraded by BTIG Research

    BTIG Research downgraded MaxCyte from Buy to Neutral

    8/11/25 9:48:40 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ATNF
    $BWAY
    $ELEV
    $LIFW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Masoud Maher

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    3/31/26 4:12:11 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Swirsky Douglas J

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    3/19/26 4:05:29 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 3 filed by new insider Jacob Gary S

    3 - OKYO Pharma Ltd (0001849296) (Issuer)

    3/18/26 8:37:54 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATNF
    $BWAY
    $ELEV
    $LIFW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Syra Health and Nora Mental Health Announce Telehealth Partnership to Expand Access to Mental and Behavioral Health Services Across Indiana

    Collaboration connects AI-powered digital behavioral health platform, Syrenity, with licensed therapists to deliver seamless, affordable careCARMEL, Ind., April 2, 2026 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today a partnership with Nora Mental Health to expand access to mental and behavioral health services across Indiana through telehealth integration with Syra Health's Syrenity behavioral health solution.

    4/2/26 4:51:00 PM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary

    Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

    HyBryte™ demonstrates more rapid and robust treatment response compared toValchlor® during 12-week treatment coursePRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the positive results of its comparability study evaluating HyBryte™ (synthetic hypericin) versus Valchlor® (mechlorethamine) for the treatment of cutaneous T-cell lymphoma (CTCL) have been published in Oncology and Therapy. 

    4/2/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 375,000 shares of MaxCyte's common stock and a service-based restricted stock unit ("RSU") award with respect to 187,500 shares of MaxCyte's common stock to Parmeet Ahuja in connection with his appointment as Chief Financial Officer of MaxCyte. The awards were granted unde

    3/31/26 4:05:00 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ATNF
    $BWAY
    $ELEV
    $LIFW
    SEC Filings

    View All

    SEC Form EFFECT filed by Soligenix Inc.

    EFFECT - SOLIGENIX, INC. (0000812796) (Filer)

    4/3/26 12:15:07 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Soligenix Inc.

    EFFECT - SOLIGENIX, INC. (0000812796) (Filer)

    4/3/26 12:15:04 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Soligenix Inc.

    EFFECT - SOLIGENIX, INC. (0000812796) (Filer)

    4/3/26 12:15:15 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BWAY
    $ELEV
    $LIFW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, CEO AND PRESIDENT Schaber Christopher J bought $20,000 worth of shares (15,132 units at $1.32), increasing direct ownership by 3,993% to 15,511 units (SEC Form 4)

    4 - SOLIGENIX, INC. (0000812796) (Issuer)

    10/3/25 1:18:09 PM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Swirsky Douglas J bought $64,500 worth of shares (50,000 units at $1.29), increasing direct ownership by 45% to 161,811 units (SEC Form 4)

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    8/13/25 7:48:49 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    President and CEO Masoud Maher bought $102,915 worth of shares (75,000 units at $1.37), increasing direct ownership by 75% to 175,000 units (SEC Form 4)

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    8/13/25 7:47:52 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ATNF
    $BWAY
    $ELEV
    $LIFW
    Financials

    Live finance-specific insights

    View All

    MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

    Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in total cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million ROCKVILLE, Md., March 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform

    3/24/26 4:05:00 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OKYO Pharma Announces Chairman and Founder Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically

    3/19/26 12:00:00 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company's ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as

    3/19/26 10:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATNF
    $BWAY
    $ELEV
    $LIFW
    Leadership Updates

    Live Leadership Updates

    View All

    MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

    ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025. "Parmeet is an exceptionally talented finance leader whose experience and expertise position him well to strengthen MaxCyte's financial operations," said Maher Masoud, Chief Executive Officer. "His deep background in

    3/23/26 8:05:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

    Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company's development program in neuropathic corneal pain (NCP), leveraging urcosimod's FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur

    2/10/26 8:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer

    Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board LONDON and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announces that, effective immediately, Robert J. Dempsey will assume the role of Chief Executive Officer. Gary S. Jacob, Ph.D. will transition to Chief Development Officer and

    1/5/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATNF
    $BWAY
    $ELEV
    $LIFW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:50:19 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:05:59 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care